Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 1999

View Archived Issues

Genzyme Molecular Oncology reports Q2 1999 highlights

Important objectives achieved during Q2 at Alza

Avant Immunotherapeutics' rotavirus vaccine effective in infants

Abbott signs paclitaxel agreement with NaPro BioTherapeutics

Approval of Busulfex injection in Canada

Atugen Biotechnology establishes North American subsidiary

Targeted Genetics and Elan form drug delivery partnership

Inhibitex's U.S. patent for S. aureus attachment gene allowed

Irinotecan approved as first-line treatment for advanced colorectal cancer in Europe

EntreMed cleared to begin phase I trials of Endostatin protein

Novo Nordisk describes new K(ATP) channel-modulating series

Abbott prepares potent, selective neuronal nicotinic acetylcholine receptor ligands

Japanese investigators discover novel antitumor/antimicrobial agent produced by actinomycete

New muscarinic compounds from Alcon especially useful for Rx of glaucoma

AHP describes synthesis and activity of novel estrogenic compounds

Anthranilide anticoagulants developed by Schering AG researchers

Genetics Institute discovers and characterizes novel bone morphogenetic proteins

Millennium obtains patent coverage for novel weight-regulating compounds

Disaccharide ester with anti-TNF-alpha effects and chemopreventive efficacy

PABSA: preclinical profile of a newly developed nonpeptide ET antagonist

No adverse influence on cardiac repolarization seen in in vitro studies with tegaserod

Adolor and SmithKline Beecham sign licensing agreement for ADL-2-1294

Cangene product for prevention of hemolytic disease approved in U.K.

New thrombin inhibitor approved in Italy for antithrombotic prophylaxis

Marked, long-lasting neuroprotective effects demonstrated for NXY-059 in rats

FDA approves SB's Kytril for prevention of radiation-induced nausea and vomiting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...